AMSTERDAM, The Netherlands, February 18 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it will release its financial results for the full year 2008 on Tuesday, February 24, 2009 at 7:00 am Central European Time (CET). To discuss these results, the Company will conduct a conference call that day at 3 p.m. CET.
The dial-in number for the Netherlands is 0800-949-4166 (toll free). The number for Germany is 0800-000-22-63 (toll free). For the UK the number is +44-207-107-0611 and for the rest of Europe: +41-91-610-5600. The number for the USA is +1-866-291-4166 (toll free). To listen to the conference call live via the internet, visit the investor relations portion of the AMT website at http://www.amtbiopharma.com. Please go to the website fifteen minutes prior to the call to register, download and install the necessary audio software.
About Amsterdam Molecular Therapeutics
AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV GMP production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of (rare) diseases that are caused by one faulty gene. AMT currently has a product pipeline with nine products at different stages of development.
Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.
|SOURCE Amsterdam Molecular Therapeutics B.V|
Copyright©2009 PR Newswire.
All rights reserved